Institute of Virology, University Hospital Ulm, D-89081 Ulm, Germany.
Antiviral Res. 2010 Feb;85(2):318-27. doi: 10.1016/j.antiviral.2009.10.004. Epub 2009 Oct 22.
Drug resistant strains of human cytomegalovirus (HCMV) in patients at risk may increasingly develop into a problem in the clinical setting. Genotypic resistance testing is becoming the method of choice, but requires previous phenotypic characterisation of each newly found mutation. In order to facilitate the interpretation of the patient's CMV sequence data, a web-based search tool was generated that links the sequence to a database containing all published UL97 (protein kinase) and UL54 (DNA polymerase) mutations and corresponding antiviral drug susceptibility phenotypes. It is reasonable to assume that HCMV drug resistance testing will provide relevant data for an adjustment of therapy and on prognosis of clinical outcome. HCMV drug susceptibility testing will become even more important once new drugs will be available for therapy allowing a wider choice of antiviral agents to treat HCMV disease. These topics will also play a pivotal role for optimising antiviral therapy of HCMV- and other viral diseases.
在有风险的患者中，人巨细胞病毒（HCMV）的耐药株可能越来越成为临床环境中的一个问题。基因型耐药性检测正成为首选方法，但需要对每个新发现的突变进行先前的表型特征分析。为了便于解释患者的 CMV 序列数据，生成了一个基于网络的搜索工具，该工具将序列链接到一个数据库，其中包含所有已发表的 UL97（蛋白激酶）和 UL54（DNA 聚合酶）突变以及相应的抗病毒药物敏感性表型。可以合理地假设，HCMV 耐药性检测将为治疗方案的调整和临床结果的预后提供相关数据。一旦有新的药物可用于治疗，HCMV 药物敏感性检测将变得更加重要，这将允许更广泛地选择抗病毒药物来治疗 HCMV 疾病。这些主题也将在优化 HCMV 和其他病毒疾病的抗病毒治疗方面发挥关键作用。
